Lorenz, Marco
Fuest, Kristina
Ulm, Bernhard
Grunow, Julius J.
Warner, Linus
Bald, Annika
Arsene, Vanessa
Verfuß, Michael
Daum, Nils
Blobner, Manfred
Schaller, Stefan J. http://orcid.org/0000-0002-6683-9584
Clinical trials referenced in this document:
Documents that mention this clinical trial
The optimal dose of mobilisation therapy in the ICU: a prospective cohort study
https://doi.org/10.1186/s40560-023-00703-1
Funding for this research was provided by:
Technische Universität München
Article History
Received: 23 August 2023
Accepted: 8 November 2023
First Online: 20 November 2023
Declarations
:
: The database has been conducted according to the Declaration of Helsinki and approved by the Ethics Committee of the Faculty of Medicine, Technical University of Munich (528/18 from 22nd Dec 2016). The inclusion criteria were age over 18 years and an expected ICU stay > 24 h, while the exclusion criterion was readmission to the intensive care unit.
: The data of critically ill patients were collected after obtaining written informed consent from them or their legal representative, in accordance with German law.
: SJS received grants and non-financial support from Reactive Robotics GmbH (Munich, Germany), ASP GmbH (Attendorn, Germany), STIMIT AG (Biel, Switzerland), ESICM (Geneva, Switzerland), grants, personal fees, and non-financial support from Fresenius Kabi Deutschland GmbH (Bad Homburg, Germany), grants from the Innovationsfond of The Federal Joint Committee (G-BA), personal fees from Springer Verlag GmbH (Vienna, Austria) for educational purposes and Advanz Pharma GmbH (Bielefeld, Germany), non-financial support from national and international societies (and their congress organisers) in the field of anesthesiology and intensive care medicine, outside the submitted work. Dr. Schaller holds stocks in small amounts from Alphabet Inc., Bayer AG, and Siemens AG; these holdings have not affected any decisions regarding his research or this study.